Login or sign up
For business

Lipideon Biotechnology AG

4.1· 10 reviews
Average ratingGreat
4.1/ 5

Based on 10 reviews

540%
430%
330%
20%
10%
Ask AI

Ask AI about Lipideon Biotechnology AG

Generated with AI from 10 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Yves Charles
Reviews 1

The Lipideon Biotechnology AG company is truly remarkable. Their commitment to innovation and quality is evident in every aspect of their work. I have been using their products for a while now and I am very impressed. The team is knowledgeable and always responsive to any inquiries. I highly recommend Lipideon to anyone in need of top-notch biotechnology solutions.

Nimitt Adhvaryu
Reviews 1

Lipideon Biotechnology AG has been an incredible partner for our research needs. Their dedication to providing top-quality products and excellent customer service is unparalleled. The team is highly knowledgeable and always goes above and beyond to assist us. We are extremely satisfied with their services.

Helen Gonzalez
Reviews 1

I have been using various biotechnology products for my research, but Lipideon Biotechnology AG stands out as the best. Their products are of exceptional quality and have consistently delivered reliable results. The customer service is exceptional, and they always assist with any queries promptly. Highly recommended!

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Lipideon Biotechnology AG

Lipideon Biotechnology AG is a Swiss stock company founded in Zurich as an ETH spin-off by Dr. Helmut Hauser in 2002. They are a drug R&D company, focusing on the treatment of arteriosclerosis and related cardiovascular diseases.

Their strategy is to develop a new class of non-absorbable drugs that inhibit cholesterol absorption in the small intestine and as a result reduce serum cholesterol levels. This carries the potential for safer and improved treatment of dyslipidemia, the main underlying cause of artherosclerosis that eventually leads to stroke and heart attacks.

Arteriosclerosis is a major health problem in Western industrialized nations affecting more than 50% of the total population and an increasing number of people in the rest of the world. Cholesterol-lowering drugs have reached worldwide sales of $ 34.7 billion in 2007.